ASTEPRO 0.15%—the Earlier the Better
- Provides rapid relief in as early as 30 to 45 minutes1,2*
- Symptom relief right at the site
- Treats nasal symptoms, including congestion, without an added decongestant3,4
- Indicated for seasonal and perennial allergic rhinitis3
- ASTEPRO 0.15% has no generic equivalent
- Contains 50% higher concentration per spray than azelastine HCI 0.1% - ASTEPRO 0.15% provides trial samples that last 3–5 days
- 1 Rx;
- 1 Copay;
- Nearly 2 Months of Therapy
Get the Allergy Information You Need–the Earlier the Better With the
Allergy Advisor
Mobile Application
For Physicians
The Earlier the Better—30 to 45 minute onset of action
For Pharmacists
Highest Tier 2 availability
For Patients
Read more about ASTEPRO 0.15% and the allergy symptom relief it delivers
*In 2 placebo-controlled SAR studies (N=1143), ASTEPRO 0.15% (2 sprays per nostril) relieved rhinitis symptoms in as early as 30 to 45 minutes, and the effect remained durable over the 4-hour assessment period.
Indication
ASTEPRO® (azelastine HCl) Nasal Spray 0.15% is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients 12 years of age and older.
Important Risk Information
- Avoid engaging in hazardous occupations requiring complete mental alertness when taking ASTEPRO Nasal Spray 0.15%
- Avoid concurrent use of alcohol or other central nervous system depressants with ASTEPRO Nasal Spray 0.15%
- In clinical studies, the most commonly reported adverse reactions, when dosed at 2 sprays per nostril once or twice daily, respectively, included bitter taste (4%, 6%), nasal discomfort (4%, 3%), epistaxis (2%, 1%), and sneezing (1%, 2%)
- Pregnancy Category C: Based on animal data, may cause fetal harm
Please see full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1‐800‐FDA‐1088
